| Objective:Evaluation of pemetrexed and gefitinib in second-line treatment of advanced non-small cell lung cancer effects and adverse reactions, so as to explore how advanced non-small cell lung cancer by the most effective treatment to maximize benefit in patients with NSCLC, to achieve the best therapeutic effect .Methods:Retrospective analysis from January 2005 to May 2010 in Cancer Hospital of Guangxi Medical University, pemetrexed, or gefitinib in second-line treatment of advanced non-small cell lung cancer in 78 cases, including pemetrexed group 39 patients received Pemetrexed 500 mg/m2; gefitinib group of 39 patients with oral gefitinib 250mg/day, patients were observed and compared short-term effect of treatment toxicity, follow-up and compare their survival time.Results:(1) response rate: The effective pemetrexed group and the gefitinib group were 8%, 10%, the latter slightly higher than the former, no significant difference between the two groups (p>0.05). (2) survival time: pemetrexed group and the gefitinib group, median progression-free survival was 3.0 months and 5.5 months with gefitinib was significantly longer, The difference was statistically significant (p<0.05); the median survival time was 8.2 months and 9.6 months with gefitinib group a long time, no significant difference between the two groups (p>0.05); (3) survival: pemetrexed group 1 year, 2-year survival rates were 25.6%, 5.1%, gefitinib group was 41.0%, 10.3% and the latter than the former, no statistical difference between two groups significance (p>0.05). (4) Toxicity: Pemetrexed group mainly as bone marrow suppression, gastrointestinal reactions, gefitinib group mainly rash and diarrhea, the two groups could be tolerated.Conclusion :Pemetrexed, or gefitinib in second-line treatment of advanced non-small cell lung cancer is safe and effective alternative treatment methods; its clinical efficacy, and toxicity was mild.
|
PDF Full Text Request